Matching-adjusted Indirect Comparison of the Efficacy of Loncastuximab Tesirine Versus Treatment in the Chemoimmunotherapy Era for Relapsed/Refractory Diffuse Large B-cell Lymphoma-Reference-Cited by-同舟云学术

Matching-adjusted Indirect Comparison of the Efficacy of Loncastuximab Tesirine Versus Treatment in the Chemoimmunotherapy Era for Relapsed/Refractory Diffuse Large B-cell Lymphoma

Published:2022-08 Issue:8 Volume:22 Page:e738-e744
ISSN:2152-2650
Container-title:Clinical Lymphoma Myeloma and Leukemia
language:en
Short-container-title:Clinical Lymphoma Myeloma and Leukemia

Author:

Hamadani Mehdi,Chen Lei,Song Yan,Xu Michael K,Liao Laura,Caimi Paolo F,Carlo-Stella Carmelo

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference38 articles.

1. American Cancer Society. Types of B-cell lymphoma. Accessed at: December 21, 2020. Accessed from: https://www.cancer.org/cancer/non-hodgkin-lymphoma/about/b-cell-lymphoma.html

2. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma;Coiffier;N Engl J Med,2002

3. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60);Pfreundschuh;Lancet Oncol.,2008

4. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma;Habermann;J Clin Oncol,2006

5. Rituximab in B-cell hematologic malignancies: a review of 20 years of clinical experience;Salles;Adv Ther,2017

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Loncastuximab Tesirine in the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma;International Journal of Molecular Sciences;2024-07-10

2. Second Line Treatment of DLBCL: Evolution of Options;Seminars in Hematology;2023-12

3. How to integrate CD19 specific chimeric antigen receptor T cells with other CD19 targeting agents in diffuse large B‐cell lymphoma?;Hematological Oncology;2023-11-08

4. Sequencing therapy in relapsed DLBCL;Hematology;2022-12-09